Cost Effectiveness Analysis of Pirfenidone For The Treatment of Mild To Moderate Idiopathic Pulmonary Fibrosis (IPF) Compared To Best Supportive Care And Nintedanib From The Italian NHS Perspective
Abstract
Authors
R Ravasio M Ferrario M Pata P Thuresson